Asia Pacific Intradermal Injections Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Method (Normal Sized Needles, Short Needle, and Without Needle), Application (Tuberculin Skin Test, Allergy Test, Local Aesthetics, and Others), End Use

Asia Pacific Intradermal Injections Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Method (Normal Sized Needles, Short Needle, and Without Needle), Application (Tuberculin Skin Test, Allergy Test, Local Aesthetics, and Others), End User (Hospitals, Diagnostic Laboratories, Academics and Research Institutes, and Others)

The Asia Pacific intradermal injections market is expected to reach US$ 1,698.4 million by 2028 from US$ 774.0 million in 2021; it is estimated to grow at a CAGR of 11.9% from 2021 to 2028. Rising acceptance of intradermal vaccination drives the growth of the market as it has several advantages over the conventional vaccination method. Intradermal vaccination helps in reducing the potential dose of antigens, improving the immune response generated by the vaccine, and decreasing the anxiety associated with the vaccination. By using intradermal injection, a large population can be vaccinated with comparatively lesser production of the vaccine while this method can vaccinate the difficult population group with comorbidities as chances of adverse events are lower than conventional vaccination. Several intradermal COVID-19 vaccines, hepatitis A vaccine, hepatitis B vaccine, Influenza vaccines, polio vaccine measles vaccine, Rabies vaccine, tetanus vaccine, yellow fever vaccine, and diphtheria-tetanus-pertussis vaccine show improvement in the overall response rate. Hence, several leading pharmaceutical and biotechnological companies are currently working on the development of intradermal injections of the new and commercially available vaccines. In 2020, Sanofi received the FDA approval for its intradermal vaccine of Influenza, named Fluzone, which is rapidly overtaking the influenza vaccine market and replacing the congenital treatments for these diseases. Along with this, Pfizer also got approval for intradermal COVID-19 vaccine named Comirnaty for vaccinating people with age more than 16 years. Therefore, the efforts made by the leading manufactures propel the growth of the market.

Based on method, the intradermal injections market is segmented into normal-sized needles, short needles, and without needles. In 2020, the normal-sized needles segment accounted for the largest share, short needles segment is expected to grow at the highest CAGR in the forecast period.

The supply chain disruptions, along with the massive demand for efficient treatments for COVID-19, have put the healthcare research industry in a crucial situation in Asia Pacific. Prohibitive measures have been taken to control the spread of the novel coronavirus. The socio-economics were also severely affected, which led to rise in negative inflation, low GDPs, and surge in unemployment in the region. Along with this, several clinical trials were also delayed due to COVID-19 pandemic, which delayed the market authorization of various products including the intradermal injections. The pandemic has affected three main aspects of the global economy: production, supply chain, and firms and financial markets. Japan, China, South Korea, India, and Australia are the most-affected countries due to the increasing number of COVID-19 cases and the associated deaths. Manufacturers and suppliers of medical devices shift their focus from regular intradermal injections to developing and supplying essentials and medical devices used for COVID-19 and respiratory issues treatments. This scenario negatively impacts the market growth. The COVID-19 pandemic is affecting the business operations of various key players operating in Asia Pacific .

The overall Asia Pacific intradermal injections market size has been derived using both primary and secondary sources. To begin the research process, exhaustive secondary research has been conducted using internal and external sources to obtain qualitative and quantitative information related to the market. The process also serves the purpose of obtaining an overview and forecast for the Asia Pacific intradermal injections market with respect to all the segments pertaining to the region. Also, multiple primary interviews have been conducted with industry participants and commentators to validate the data, as well as to gain more analytical insights into the topic. Participants of this process include industry experts such as VPs, business development managers, market intelligence managers, and national sales managers, along with external consultants such as valuation experts, research analysts, and key opinion leaders, specializing in the Asia Pacific intradermal injections market. Companies adopt a few strategies, such as mergers and acquisitions and market initiatives, which promotes market growth. BD, West Pharmaceutical Services, Inc., Terumo Corporation, NanoPass, Pharmajet, Idevax, EUNSUNG GLOBAL, Crossject, Cardinal Health Inc., and Hindustan Syringes and Medical Devices Ltd are among the major players operating in the market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific intradermal injections market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific intradermal injections market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.